KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Efficacy and safety of adjuvant transarterial chemoembolization in high-risk HCC after curative hepatectomy: a phase III RCT protocol.

Chao-Man Huang, Shu-Chang Chen, Yi-He Yan, Chuang Qin, Shu-Qun Li, Ze Su, Xiao-Feng Dong, Teng-Meng Zhong, Fan-Jian Zeng, Hong-Bing Yao, Shao-Ping Liu, Pei-Sheng Wu, Ning Peng, Jie Liu, Liang Ma, Jian-Hong Zhong

ILIVER 5(2) 100236

PMID42125606
PMCIDPMC13158760
DOI10.1016/j.iliver.2026.100236
发表日期2026-05-13
摘要

摘要

INTRODUCTION: Hepatocellular carcinoma (HCC) remains associated with a high risk of recurrence, with 5-year recurrence rates approaching 70% after curative hepatectomy. The Chinese Liver Cancer Staging guideline strongly recommend transarterial chemoembolization (TACE) as an adjuvant therapy to reduce postoperative recurrence and improve overall survival. However, its clinical benefit remains controversial, as guidelines from other regions do not support routine use of adjuvant TACE. This discrepancy may reflect the possibility that adjuvant TACE primarily facilitates detection of intrahepatic residual lesions through digital subtraction angiography (DSA), rather than conferring direct therapeutic benefit from embolic or chemotherapeutic agents. METHODS AND ANALYSIS: This multicenter, phase III randomized controlled trial will enroll 442 eligible participants, who will be randomly assigned in a 1:1 ratio to either an adjuvant TACE group or an intensive follow-up group. The primary endpoint of this study is to investigate whether adjuvant TACE could improve recurrence-free survival (RFS) in high-risk HCC patients following curative hepatectomy. The key secondary endpoints include the safety and tolerability of adjuvant TACE, as well as the effects of adjuvant TACE versus intensive follow-up on overall survival, median RFS, and time to tumor recurrence. This trial may addresses the critical clinical controversy regarding adjuvant TACE by excluding patients with residual tumor staining on DSA, to ensure genuine curative resection. The results will deliver high-quality evidence to clarify the efficacy and safety of adjuvant TACE, and standardize postoperative adjuvant strategies.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。